Get the Stockscreener App
172.59
0.71%
-1.23
After Hours:
172.59
Overview
News
Price History
Option Chain
Financials
Why BDX Down?
Discussions
Forecast
Stock Split
Dividend History
Becton Dickinson Co stock is traded at $172.59, with a volume of 3.36M.
It is down -0.71% in the last 24 hours and down -16.40% over the past month.
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.
See More
Previous Close:
$173.82
Open:
$173.54
24h Volume:
3.36M
Relative Volume:
1.23
Market Cap:
$49.47B
Revenue:
$20.87B
Net Income/Loss:
$1.50B
P/E Ratio:
32.94
EPS:
5.24
Net Cash Flow:
$2.59B
1W Performance:
+0.71%
1M Performance:
-16.40%
6M Performance:
-22.22%
1Y Performance:
-23.90%
1-Day Range:
$171.65
$173.80
1-Week Range:
$171.65
$176.43
52-Week Range:
$163.33
$251.99
Becton Dickinson Co Stock (BDX) Company Profile
Name
Becton Dickinson Co
Sector
Industry
Phone
(201) 847-6800
Address
ONE BECTON DR, FRANKLIN LAKES
Compare BDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
172.59 | 49.12B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ISRG
Intuitive Surgical Inc
|
552.34 | 193.38B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
85.94 | 42.79B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
244.79 | 35.61B | 5.02B | 1.31B | 1.56B | 8.91 |
|
BAX
Baxter International Inc
|
30.50 | 15.46B | 11.89B | -560.00M | 191.00M | -1.10 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-25 | Downgrade | Citigroup | Buy → Neutral |
| May-02-25 | Downgrade | Goldman | Buy → Neutral |
| May-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-01-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-24-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| May-05-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-12-23 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jan-03-23 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-22 | Upgrade | Citigroup | Sell → Neutral |
| Jul-11-22 | Downgrade | Citigroup | Neutral → Sell |
| Jun-24-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-18-22 | Resumed | Raymond James | Mkt Perform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Dec-08-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-09-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-01-20 | Resumed | Goldman | Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-07-20 | Downgrade | Cowen | Outperform → Market Perform |
| Feb-07-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Feb-07-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Feb-06-20 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-08-20 | Downgrade | Barclays | Overweight → Equal Weight |
| May-13-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-07-18 | Initiated | Deutsche Bank | Buy |
| Oct-16-18 | Initiated | Barclays | Equal Weight |
| Jun-21-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Jan-19-18 | Resumed | BofA/Merrill | Buy |
| Jan-05-18 | Upgrade | Citigroup | Sell → Neutral |
| Jan-05-18 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Dec-29-17 | Reiterated | Deutsche Bank | Buy |
View All
Becton Dickinson Co Stock (BDX) Latest News
Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - Yahoo Finance
Becton, Dickinson and Company to Initiate Real-World Patient Data Registry for the Rotarex?? Atherectomy System in Treatment of Peripheral Artery Disease - marketscreener.com
BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease - BD Newsroom
Becton Dickinson’s SWOT analysis: stock’s future hangs on life sciences spin-off - Investing.com
Saudi Arabia Research Antibodies Market Report 2025-2030, - GlobeNewswire
Saudi Arabia Research Antibodies Market Report 2025-2030, Competitive Analysis of Cell Signaling Technology, Salima Trading, AJ Jeel Medical & Trading Co, Becton, Dickinson and Co, and Merck - Yahoo Finance
AC Health, Becton Dickinson team up to elevate healthcare standards across Asia - Bilyonaryo Business News
Becton Dickinson stock rating cut by Citi to Neutral, target to $185 - Investing.com India
Becton, Dickinson & Co (BDX) Is Paying a $85M Settlement to Investors — Here’s How to Get Your Share - TradingView
Accenture To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut b - GuruFocus
Becton Dickinson (BDX) Receives Downgrade and Price Target Cut by Citigroup | BDX Stock News - GuruFocus
6 Analysts Have This To Say About Becton Dickinson - Benzinga
Becton Dickinson (BDX) Downgraded by Citi to Neutral | BDX Stock News - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challen - GuruFocus
Becton Dickinson (BDX) Downgraded by Citi Amid Quarterly Challenges | BDX Stock News - GuruFocus
Citigroup Downgrades Becton Dickinson and Co. to Neutral From Buy, Adjusts PT to $185 From $217 - marketscreener.com
BD aims to secure slice of medical technology market - BusinessMirror
Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs' - BD Newsroom
FBI probes North Canaan suspicious package that contaminated hundreds: What we know and don't know - CT Insider
Becton, Dickinson and Company Stock: Analyst Estimates & Ratings - inkl
Becton, Dickinson And Company Stock: Analyst Estimates & Ratings - Barchart.com
Becton, Dickinson and Company (BDX): Among the Most Oversold Stocks to Buy According to Billionaires - Insider Monkey
Argus Adjusts Price Target on Becton Dickinson and Co. to $220 From $270, Maintains Buy Rating - marketscreener.com
Edwards Lifesciences Completes Sale of Critical Care - Quantisnow
Becton Dickinson Sues Baxter Over Infusion Pump Patents - Law360
Becton Dickinson at Bank of America Conference: Navigating Challenges and Opportunities - Investing.com Nigeria
Transcript : Becton, Dickinson and Company Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10 - marketscreener.com
Judge declares mistrial in punitive damages phase in Walker v. BD - The Covington News
Becton Dickinson Says Baxter Infringes Infusion-Pump Patents (1) - Bloomberg Law News
Sterile Lancets Market Set to Grow | Key Players: Roche, Becton Dickinson, Medtronic - openPR.com
Becton Dickinson (BDX) Unveils Advanced Cell Analyzer - GuruFocus
BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies - marketscreener.com
First Eagle Investment's Strategic Moves: Spotlight on Becton Dickinson & Co - Yahoo Finance
Becton Dickinson & Co (BDX) Shares Up 3.73% on May 12 - GuruFocus
Becton Dickinson, Spotify, Arvinas, Twilio, Lumen: Trending by Analysts - MSN
The Strong Earnings Posted By Becton Dickinson (NYSE:BDX) Are A Good Indication Of The Strength Of The Business - Yahoo
Morgan Stanley Lowers Becton, Dickinson and Company (NYSE:BDX) Price Target to $196.00 - Defense World
SEC Form 4 filed by Director Byington Carrie L - Quantisnow
Becton, Dickinson downgraded at more firms following Q2 results - MSN
Becton Dickinson downgraded to Neutral from Buy at Goldman Sachs - MSN
Jim Cramer on Becton, Dickinson and Company (BDX): “A Shocking Miss for This Once-Reliable Med Tech Giant” - Insider Monkey
Mistrial declared after jury awards $50M in landmark toxic gas case - AJC.com
Becton Dickinson (NYSE:BDX) Sees 18% Price Dip Over Last Week - Yahoo Finance
Becton Dickinson (BDX) Price Target Lowered by Morgan Stanley | BDX Stock News - GuruFocus
Investors Can Still File Late Claims for Becton, Dickinson & Co $85M Settlement Payouts - TradingView
Morgan Stanley Adjusts Price Target on Becton, Dickinson and Company to $196 From $280, Maintains Overweight Rating - marketscreener.com
Covington resident wins $20 million in case against Becton Dickinson - The Covington News
Is Becton, Dickinson and Company's (NYSE:BDX) Stock Price Struggling As A Result Of Its Mixed Financials? - simplywall.st
Medical-products maker Becton Dickinson says cuts in global research funding have hurt sales - MSN
Becton Dickinson Co Stock (BDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):